Literature DB >> 9624478

Initial concentration-time profile of gentamicin determines efficacy against Enterobacter cloacae ATCC 13047.

C R Rayner1, L L Ioannides-Demos, J A Brien, L L Liolios, W J Spicer.   

Abstract

In vitro studies were designed to investigate the influence of peak drug concentration (Cmax), the area under the concentration-time curve (AUC), and, consequently, the trough concentration on the bactericidal effects of gentamicin against Enterobacter cloacae (MIC, 0.5 mg/liter) by simulating bolus versus infusion administration and bolus dosing with altered drug clearance. Bacteria in the lag phase were exposed to gentamicin concentration-time profiles modelling either bolus or infusion dosing (AUC constant, Cmax changing) with 30-min postdose peak concentrations (Cpeak30) of 4, 6, 8, and 10 mg/liter or bolus dosing with normal and double drug clearance (Cmax constant, AUC changing) corresponding to normal clearance profiles with Cpeak30 of 6 and 8 mg/liter. Exposure to gentamicin caused early bactericidal effects apparent by 2 h, followed by variable bacteriostatic and recovery phases. Exposure to bolus profiles resulted in greater bactericidal activity than the corresponding infusion profile up to a Cpeak30 of 8 mg/liter. At a Cpeak30 of 10 mg/liter, there were no differences in bactericidal effect. Double clearance profiles had a reduced bactericidal effect at 6 mg/liter compared to the corresponding normal clearance profile, but no differences in bactericidal effect were observed for 8-mg/liter double and normal clearance profiles. These results suggest that the initial exposure (i.e., 0 to 30 min) is a more important determinant for bacterial killing than the AUC or trough concentration for this bacterium. Subject to confirmation of these findings with other gram-negative bacteria, to optimize aminoglycoside efficacy the initial exposure (Cmax) should be maximized by giving higher doses or bolus administration at intervals which may not produce detectable trough concentrations. Clinical trials with a broad range of patients, especially those with higher clearance, would confirm these in vitro observations and define optimal dosing recommendations.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9624478      PMCID: PMC105606     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  The postantibiotic effect: a review of in vitro and in vivo data.

Authors:  G G Zhanel; D J Hoban; G K Harding
Journal:  DICP       Date:  1991-02

2.  Comparison of gentamicin dosing regimens using an in-vitro model.

Authors:  E J Begg; B A Peddie; S T Chambers; D R Boswell
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

3.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

4.  Bactericidal effect of gentamicin peak concentration provides a rationale for administration of bolus doses.

Authors:  A J McLean; L L IoannidesDemos; S C Li; E B Bastone; W J Spicer
Journal:  J Antimicrob Chemother       Date:  1993-08       Impact factor: 5.790

5.  Kill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing.

Authors:  E B Bastone; S C Li; L L Ioannides-Demos; W J Spicer; A J McLean
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

6.  Surface action of gentamicin on Pseudomonas aeruginosa.

Authors:  J L Kadurugamuwa; A J Clarke; T J Beveridge
Journal:  J Bacteriol       Date:  1993-09       Impact factor: 3.490

Review 7.  Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man.

Authors:  W A Craig
Journal:  J Antimicrob Chemother       Date:  1993-05       Impact factor: 5.790

8.  Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.

Authors:  R D Moore; P S Lietman; C R Smith
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

Review 9.  Aminoglycoside uptake and mode of action-with special reference to streptomycin and gentamicin. II. Effects of aminoglycosides on cells.

Authors:  R E Hancock
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

10.  Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections.

Authors:  W A Craig; J Redington; S C Ebert
Journal:  J Antimicrob Chemother       Date:  1991-05       Impact factor: 5.790

View more
  1 in total

1.  A concept for pharmacokinetic-pharmacodynamic dosage adjustment in renal impairment: the case of aminoglycosides.

Authors:  D Czock; M Giehl; F Keller
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.